Jupiter Endovascular, Inc., a Menlo Park, CA-based medical know-how startup, exited stealth mode with a $21M new spherical of financing.
Sonder Capital was a key participant within the spherical that included participation from a number of strategic buyers.
The funding will probably be used to assist the corporate’s upcoming pivotal trial for Pulmonary Embolism and improvement of extra scientific purposes of the Endoportal ManagementTM know-how.
Jupiter is growing a brand new class of endovascular procedures utilizing Endoportal ManagementTM to deliver the precision and management of direct surgical entry to catheter-based interventions.
The corporate has appointed Carl J. St. Bernard as Jupiter Endovascular’s Chief Government Officer. St. Bernard, an trade veteran with a wealth of medical know-how management expertise, joins Jupiter from Alta Biomaterials, the place he held the position of President and CEO. He has over 30 years of expertise within the life sciences enviornment and has held senior govt positions at CeloNova BioSciences, Tryton Medical, Johnson & Johnson Imaginative and prescient, LifeCell, Cordis, and GE Healthcare. He’s additionally an AdvaMed board director.
FinSMEs
15/08/2024
